Nov 21, 2019

Breast Cancer Update, Issue 4, 2019 — Part 1: Our interview with Dr Rugo highlights the following topics as well as cases from her practice:

• Biology of triple-negative breast cancer (TNBC); implications for therapeutic decision-making (00:00)
• Median overall survival estimates for patients with metastatic TNBC (03:55)
• Survival outcomes for patients with metastatic ER-positive and HER2-positive breast cancer (05:42)
• Case: A woman in her early 30s with localized TNBC receives neoadjuvant chemotherapy on the control arm of the I-SPY 2 trial (08:27)
• Genetic testing for patients with TNBC (12:58)
• Fertility preservation in young women undergoing therapy for breast cancer (14:40)
• Perspective on the use of GnRH agonists for premenopausal women with TNBC (16:27)
• Importance of providing support to patients coping with a diagnosis of TNBC (18:31)
• I-SPY 2 trial: Neoadjuvant and personalized adaptive novel agents to treat breast cancer (20:36)
• Novel agents under evaluation in the I-SPY 2 trial (23:30)
• Investigation of immune checkpoint inhibitor combination approaches (25:43)
• Cooling caps to reduce chemotherapy-related hair loss (28:25)
• Use of frozen gloves and socks to lessen chemotherapy-induced peripheral neuropathy (31:26)
• Coping with the side effects of chemotherapy (32:32)
• Case: A woman in her early 60s with metastatic TNBC is treated with atezolizumab and nab paclitaxel (36:12)
• Importance of accurately determining tumor of origin in patients who present with metastatic disease after diagnosis of multiple primary cancers (39:10)
• Approach to genetic testing for women with metastatic TNBC (41:51)
• Use of genetic test results in clinical decision-making (45:57)
• Improvement in overall survival with atezolizumab and nab paclitaxel for patients with PD-L1-positive TNBC (47:33)
• Response and tolerability of atezolizumab with nab paclitaxel on the IMpassion130 study (50:37)
• Thyroid dysfunction associated with immune checkpoint inhibitors (53:26)
• Biologic rationale for the investigation of immune checkpoint inhibitors in breast cancer (56:36)
• Activity of anti-PD-1/PD-L1 antibodies in patients with breast cancer (58:25)
• Design, eligibility and outcomes of the IMpassion130 study evaluating atezolizumab with nab paclitaxel as first-line therapy for advanced TNBC (1:01:01)
• Therapeutic approach for patients with TNBC and BRCA mutations (1:06:05)
• Case: A woman in her early 40s with a germline BRCA1 mutation receives chemotherapy followed by maintenance olaparib for metastatic TNBC (1:09:16)
• Efficacy of olaparib and talazoparib for patients with advanced breast cancer and a germline BRCA mutation (1:13:16)
• Tolerability profile of olaparib versus talazoparib (1:17:22)
• Emerging data with the novel antibody-drug conjugates sacituzumab govitecan, trastuzumab deruxtecan and ladiratuzumab vedotin for advanced breast cancer (1:19:39)

CME Information and select publications